Glycidol

Glycidol

SCHEMBL543441

Nc1ccn(CO)c(=O)n1.OCC1CO1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.55
LMNA P02545 5/20 0.45
PDE3A Q14432 3/20 0.45
CACNA1F O60840 2/20 0.45
ALB P02768 2/20 0.45
MAPT P10636 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
THRB P10828 1/20 0.44
MTOR P42345 1/20 0.44
MDM2 Q00987 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
PDE4D Q08499 1/20 0.41
SLC29A1 Q99808 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236000 0.84 FGFR1 (0.51) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL27292735 0.83 FGFR1 (0.69) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL8925507 0.80 FGFR1 (0.55) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL8093647 0.80 LMNA (0.57) FGFR1LMNAPDE3ACACNA1FALB
Phosphoric Acid SCHEMBL27689268 0.79 FGFR1 (0.57) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL25651884 0.78 FGFR1 (0.45) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL20012360 0.75 LMNA (0.58) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL9492118 0.74 LMNA (0.51) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL22110470 0.74 LMNA (0.51) FGFR1LMNAPDE3ACACNA1FALB
SCHEMBL16446911 0.74 FGFR1 (0.47) FGFR1LMNAPDE3ACACNA1FALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110676-B2 Prodrugs activated by RNA-dependent DNA-polymerases PROTERA S.R.L. (IT) 2012-02-07 US claimed
US-20080300215-A1 Prodrugs Activated by Rna-Dependent Dna-Polymerases PROTERA S.R.L. (IT) 2008-12-04 US claimed
EP-1778254-A2 PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES Protera S.R.L. (IT) 2007-05-02 EP claimed
WO-2006013203-A2 PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES PROTERA S.R.L. (IT) 2006-02-09 WO claimed
US-8110676-B2 Prodrugs activated by RNA-dependent DNA-polymerases PROTERA S.R.L. (IT) 2012-02-07 US disclosed
US-20080300215-A1 Prodrugs Activated by Rna-Dependent Dna-Polymerases PROTERA S.R.L. (IT) 2008-12-04 US disclosed
EP-1778254-A2 PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES Protera S.R.L. (IT) 2007-05-02 EP disclosed
WO-2006013203-A2 PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES PROTERA S.R.L. (IT) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300215-A1 Prodrugs Activated by Rna-Dependent Dna-Polymerases TERT, POLRMT, POLI FGFR1 4530/4885LMNA 801/4885PDE3A 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.